EMG
PVLA

Ellington Management Group’s Palvella Therapeutics PVLA Stock Holding History

Ellington Management Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-558
Closed -$304K – 904
2018
Q1 		$304K Buy
+558
New +$345K 0.02% 591

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Ellington Management Group's PVLA Position: Q2 2018 in Review

Ellington Management Group sold out of Palvella Therapeutics (PVLA) in Q2 2018, closing a stake of 558 shares — an estimated $304K sold.

Ellington Management Group first reported a position in PVLA in Q1 2018 and held it in 1 quarter. The position peaked at $304K in Q1 2018. 115 funds tracked by Wall St. Rank hold PVLA as of Q2 2018.

  • Ellington Management Group reported no remaining Palvella Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Ellington Management Group sold 558 Palvella Therapeutics shares in Q2 2018, an estimated $304K.
  • Ellington Management Group first reported a position in Palvella Therapeutics in Q1 2018 and held it in 1 quarter.
  • Ellington Management Group's Palvella Therapeutics position peaked at $304K in Q1 2018.
  • 115 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.